GSR Leads $100M Private Placement into Nasdaq-listed MEI Pharma to Launch First Institutional Litecoin Treasury Strategy Alongside Charlie Lee
GSR, crypto's capital markets partner, today announced an investment and strategic partnership with MEI Pharma, Inc. (NASDAQ:MEIP) ('MEI'), in which it will serve as both strategic advisor and digital asset treasury manager. The $100 million private investment in public equity (PIPE) into MEI represents a significant step toward institutionalizing Litecoin as a treasury asset.
GSR will work closely with Litecoin (LTC) creator Charlie Lee, who brings deep technical credibility and a long-term perspective on Litecoin's evolution, with support from the Litecoin Foundation. Lee and a GSR appointee will also join MEI's Board of Directors. This initiative follows MEI's previously announced review of strategic alternatives and reflects its new mission in alignment with both the Litecoin Foundation and GSR's digital asset management platform.
'Litecoin has consistently delivered a stable, low-cost, and accessible network for over a decade,' said Charlie Lee, creator of Litecoin. 'With leading global transaction volume on platforms like BitPay, Litecoin is trusted by users and integrated across retail and payments. This partnership with GSR and MEI brings that utility and mission into an institutional setting for the first time.'
MEI's leadership is driving this strategic shift, viewing the partnership as a bridge between public markets and crypto-native innovation. With GSR serving as asset manager and execution partner, MEI will be well-positioned to manage LTC as a treasury asset.
'This initiative represents the first time a public company is aligning its treasury strategy with Litecoin at an institutional level,' said Joshua Riezman, US Chief Strategy Officer, GSR. 'It reflects rising institutional confidence in LTC's credibility, resilience, and regulatory clarity.'
'There is already meaningful institutional interest in Litecoin, but few mechanisms exist to access it in a secure and structured way,' said Quynh Ho, Head of Venture Investment, GSR. 'This investment is designed to close that gap by enabling access to an asset with remarkable staying power.'
With GSR as an investor, strategic advisor, and asset manager, the collaboration creates potential momentum for LTC's future growth in decentralized finance. GSR's broader involvement in the space, including the incubation of the Polygon-based protocol Katana, highlights its expertise in supporting emerging ecosystems.
Charlie Lee and GSR acted as lead investors, alongside participation from the Litecoin Foundation and prominent crypto venture capital firms and infrastructure providers, including Mozayyx, Parafi, HiveMind, Primitive, RLH Capital, Delta Blockchain, and CoinFund, among other financial institutions.
GSR continues to invest in the broader digital asset ecosystem, offering capital solutions, liquidity, and strategic advisory services to partners at all stages of growth.
About GSR
GSR is crypto's capital markets partner, delivering market-making, institutional-grade OTC trading, and strategic venture backing to founders and institutions. With more than a decade of experience, we provide strategic guidance, market intelligence, and access to a global network to help teams scale.
VP Public Relations
GSR
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
JP Morgan Raises Trimble (TRMB) Price Target, Maintains Overweight Rating
Trimble Inc. (NASDAQ:TRMB) is one of the Best Industrial Automation Stocks to Buy for the Next Decade. JPMorgan has raised its price target on Trimble Inc. (NASDAQ:TRMB) to $95 from $88, maintaining its Overweight rating on the stock. The investment bank cited growing strength in the broader machinery group, driven by a mix of favorable legislative developments and macroeconomic shifts. A worker at a remote location using Automated Application Technology with their tablet and scanner. According to JPMorgan analysts, the recent passage of the 'One Big Beautiful Bill', which restores 100% bonus depreciation, has revived investor enthusiasm for capital-intensive sectors. This, combined with the delayed implementation of key tariffs and increasing confidence in forthcoming interest rate cuts from the Federal Reserve, has created a tailwind for machinery and equipment names. Historically, machinery stocks have performed well ahead of initial rate cuts, and JPMorgan believes this cycle will follow the same pattern. As such, the firm is recommending that investors increase exposure to the sector, with Trimble Inc. (NASDAQ:TRMB) standing out as a top pick. Trimble shares have already seen notable gains in recent weeks, reflecting optimism about demand recovery and structural investment in automation technologies across industries. With a strong presence in construction tech, geospatial software, and precision agriculture, Trimble is positioned to benefit from long-term infrastructure modernization and digital transformation trends. Trimble enables industrial automation through advanced GPS, construction tech, and geospatial software critical to precision workflows in manufacturing and infrastructure. While we acknowledge the potential of TRMB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Consumer Defensive Stocks to Buy Now. Disclosure: None. This article is originally published at Insider Monkey.
Business Upturn
26 minutes ago
- Business Upturn
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) — Tevogen ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197) titled, 'Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models.' This patent covers technology developed by that leverages machine learning algorithms, powered by Microsoft (Nasdaq: MSFT) and Databricks intended to rapidly and accurately identify peptides with strong immune system interactions. Identifying these peptides is critical in developing targeted therapies for a variety of diseases, including cancers and infectious diseases. Traditional methods for identifying immunologically active peptides often face significant limitations, such as overlooking critical human genetic diversity factors like age, sex, race, and ethnicity. proprietary approach may overcome these challenges by: Efficiently screening and ranking potential peptides based on their immunological activity. Eliminating peptides likely to be ineffective due to self-tolerance or human genome overlap. Continuously refining predictions using real-world data to train and enhance machine learning models. 'I'm pleased with continued progress in strategically harnessing artificial intelligence in support of our cell therapy development,' said Dr. Ryan Saadi, Founder and CEO of Tevogen. 'Leveraging AI to accelerate discovery, shorten development timelines, and reduce costs is essential to our mission of delivering commercially attractive, economically viable, and cost-effective personalized T cell therapies.' Forward Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
29 minutes ago
- Yahoo
After Losing More Than $1 Trillion in Market Cap Earlier This Year, Nvidia Has Reclaimed Its Position as the World's Most Valuable Company. Here's Why I Think It's Headed Even Higher.
Key Points Following the stock's swift sell-off in early 2025, Nvidia has recovered just as quickly to reach a new all-time high. Thanks to that rebound, the chip giant is once again the most valuable company in the world as measured by market cap. Nvidia has a number of new catalysts that have yet to contribute meaningful growth to the business. 10 stocks we like better than Nvidia › The first several months of 2025 were painful for Nvidia (NASDAQ: NVDA) investors. Back in April, Nvidia's market capitalization bottomed around $2.3 trillion -- representing a 37% decline from the peak it reached just three months earlier. There were a number of factors that influenced Nvidia's sell-off. First was the emergence of a Chinese start-up called DeepSeek, which claimed to build its impressive R1 artificial intelligence (AI) model using older Nvidia chips. This led some investors to fear that Nvidia's newest, high-priced chipsets may no longer be necessary to support the world's growing AI infrastructure. Beyond DeepSeek, investors were also concerned about how new U.S. tariff policies would impact Nvidia's growth prospects overseas. Lastly, rising competition from Advanced Micro Devices, as well as investment in custom silicon from cloud hyperscalers like Microsoft, Amazon, and Alphabet, gave credence to the idea that Nvidia's best days may be in the rearview mirror. However, following a bullish earnings report back in May, investors seem to now consider these concerns overblown. As of July 11, Nvidia's market cap is just over $4 trillion -- making the semiconductor darling the most valuable business in the world once again. With shares rocketing higher, it's worth taking a look at Nvidia's valuation trends to assess whether the stock remains a good buy or if some investors have missed the boat. Analyzing Nvidia's valuation multiples The chart below illustrates Nvidia's price-to-sales (P/S) and forward price-to-earnings (P/E) multiples over the last few years. As you can see, Nvidia's current P/S and forward P/E ratios are well below the highs previously seen during the AI revolution. To be clear, this does not necessarily mean Nvidia is destined to reach or eclipse its prior P/S of 46 and forward earnings multiple of 51. Furthermore, the company's multiples do not necessarily need to expand in order for the company to increase in value. Nvidia's future valuation hinges on the company's growth potential. Lets explore some catalysts that could lead to meaningful growth for Nvidia over the next several years. What catalysts does Nvidia have? For the last few years, the majority of Nvidia's growth has come from its data center operation. Nvidia designs industry-leading GPUs that are used by the world's largest businesses in their development of generative AI capabilities. However, the company has a number of opportunities outside of AI data centers that investors may be overlooking. First, companies such as Tesla and Alphabet have invested billions developing autonomous driving technology. Nvidia is tapped into self-driving cars too -- during the first quarter, it generated $567 million in sales from its automotive services businesses. This represented 72% year-over-year growth, giving the segment an annual revenue run rate of $2.3 billion. To put that into perspective, Nvidia's data center business generates well over $100 billion in sales per year. While the automotive segment is unlikely to become as large as the data center business, I'm confident Nvidia has much more room to grow in this area as autonomous vehicle technology continues to scale. With partners including General Motors, Toyota Motor, Mercedes-Benz, Volvo, Rivian Automotive, BYD and many more, Nvidia stands to benefit from the broader rise of self-driving cars, making the company an agnostic beneficiary of the autonomous vehicle opportunity. Another related opportunity is the rise of AI-powered robotics. Companies such as Tesla and Figure AI are building humanoid robots that are meant to facilitate the workforce in labor-intensive environments such as warehouses. Moreover, Amazon is integrating a number of robotics-driven processes into its fulfillment centers in order to drive more efficiency. Nvidia is an investor in Figure AI, and CEO Jensen Huang has touted robotics as multitrillion-dollar opportunity within the broader AI realm. Lastly, while companies such as IonQ and Rigetti Computing fetch most of the attention in the world of quantum computing, Nvidia is not a name investors want to sleep on. Outside of hardware, Nvidia also develops an AI software platform called CUDA. The company has quietly adapted this architecture for other applications with quantum computing being one of them via the introduction of the CUDA-Q platform. Is Nvidia stock a buy right now? One thread that stitches autonomous driving, robotics, and quantum computing together is that all three technologies are incredibly nascent. Their commercial reach remains limited, but each has the potential to disrupt a number of industries on a global scale. And Nvidia sits right in the middle with the chips and software to power these technologies. With Nvidia's valuation multiples down from their peak levels, many investors may see the business as a maturing operation. Others may have doubts around Nvidia's ability to continue accelerating growth and are therefore pricing in some of this risk. Given the ideas explored above, I think Nvidia stock is headed higher in the long-run. The resiliency of the company's share price combined with numerous opportunities capable of unlocking further revenue and profits has me optimistic that Nvidia will eclipse its current valuation in the long run. For these reasons, I think now is a compelling time to scoop up some shares of Nvidia and prepare to hold on tight. The next growth wave appears to be just getting started. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $679,653!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,046,308!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Adam Spatacco has positions in Alphabet, Amazon, Microsoft, Nvidia, and Tesla. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Amazon, Microsoft, Nvidia, and Tesla. The Motley Fool recommends BYD Company and General Motors and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. After Losing More Than $1 Trillion in Market Cap Earlier This Year, Nvidia Has Reclaimed Its Position as the World's Most Valuable Company. Here's Why I Think It's Headed Even Higher. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
